The global orphan drug market is expanding rapidly, reaching 16 trillion yuan in 2024

[analysis of the market of pharmaceutical stations] orphan disease is also called rare disease, which is a kind of disease with very low incidence rate, but various diseases and serious symptoms According to the definition of the World Health Organization (who), the rare disease is the disease that the number of patients accounts for 0.65 ‰ - 1 ‰ of the total population It is reported that as many as 7000 diseases have been defined as rare diseases, of which only about 400 rare diseases have corresponding treatment drugs approved Globally, the total number of patients with rare diseases has reached 300 million The author understands that the global orphan drug market is expanding rapidly, with an average annual growth rate of 7.1% in 2008-2017; however, the relevant report points out that the global orphan drug market in 2018 is $131 billion It is expected that in the next six years (2019-2024), the market will grow rapidly at an annual compound growth rate of 12.3%, twice the growth rate of the non orphan drug market (6%) in the same period, reaching 242 billion US dollars (about 1629.749 billion yuan) by 2024, and its share in the prescription drug market will exceed 20%, reaching 20.3% The market scale of orphan drugs has steadily increased the share of the whole prescription drug market, and China is also paying more attention to the orphan drug market On February 11, 2019, the executive meeting of the State Council deployed measures to strengthen early diagnosis and treatment of cancer and guarantee of drug use, and decided to give value-added tax preference to drugs with rare diseases From March 1, for the first batch of 21 drugs with rare diseases and 4 APIs, the import value-added tax will be reduced by 3% with reference to anticancer drugs, and the domestic value-added tax can be calculated by 3% simple method The benefits of tax reduction will also bring more beautiful performance to the reports of related companies In addition, celgene (New based Biopharmaceutics) will replace Novartis (Novartis) in 2022 as the enterprise ranking the sales of orphan drugs, and Bristol Myers Squibb (Bristol Myers precious) will take the second place Specifically, the top 10 pharmaceutical companies in the orphan drug market in the future are Xinji, Bristol Myers Squibb, Novartis, Roche, Johnson & Johnson, shire, Aberdeen, Merck, alexion and Pfizer There are 7 multinational pharmaceutical groups, the top 5 market enterprises will occupy 30.6% of the market share of orphan drugs, and the concentration of orphan drugs industry will be further improved Some experts also predict that in 2024, the sales volume of Xinji's Oncology orphan drugs will reach 12.6 billion US dollars Although the sales volume will remain stable in 2018-2024, the market share will decline by 50% Xinji, Aberdeen and Johnson & Johnson will occupy 30% of the market GlaxoSmithKline, rexahn and blueprint medicines have changed greatly All three companies have no oncology orphan drug products in 2018, but they will occupy a certain market share in 2024, which means that the oncology orphan drug market will become more fragmented in the future In terms of products, imbruvica and revimid will become orphan drug products, accounting for 60% of the sales of orphan drugs of the top 10 pharmaceutical companies Other key drivers of the market include drugs such as vyndaqel and hemlibra Valuepharma analyzed the orphan drugs in research (phase III to submitted) according to the net present value (NPV) Among the five drugs, the NPV of the drugs in research was as high as $53 billion, among which vertex's triple therapy for cystic fibrosis ranked first In the research of orphan drugs, the development of drugs for oncology indications plays a leading role In addition, in 1983-2018, 70% of orphan drug qualifications were granted to oncology, among which non Hodgkin lymphoma (NHL) granted more orphan drug qualifications (270), followed by acute myeloid leukemia (220) and pancreatic cancer (189) In 2018, these three diseases were also awarded many orphan drug qualifications, highlighting the significant unmet medical needs in these areas.